Get started
Author

Gerson Peltz

First-Line Lorlatinib or Crizotinib in Advanced ALK -Positive Lung Cancer
2020 · Alice T. Shaw, Todd M. Bauer, et al. · New England Journal of Medicine · 1,101
PDF
Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study
2018 · Benjamin J Solomon, Benjamin Besse, et al. · The Lancet Oncology · 791
Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1–2 trial
2019 · Alice T Shaw, Benjamin J Solomon, et al. · The Lancet Oncology · 359
The role of fat mass index in determining obesity
2010 · Gerson Peltz, Maria Teresa Aguirre, et al. · American Journal of Human Biology · 191
Clinical Management of Adverse Events Associated with Lorlatinib
2019 · Todd M. Bauer, Enriqueta Felip, et al. · The Oncologist · 166
PDF
Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial results
2023 · Kelly C. Goldsmith, Julie R. Park, et al. · Nature Medicine · 144
PDF
Post Hoc Analysis of Lorlatinib Intracranial Efficacy and Safety in Patients With ALK -Positive Advanced Non–Small-Cell Lung Cancer From the Phase III CROWN Study
2022 · Benjamin J. Solomon, Todd M. Bauer, et al. · Journal of Clinical Oncology · 139
PDF
Brain Penetration of Lorlatinib: Cumulative Incidences of CNS and Non-CNS Progression with Lorlatinib in Patients with Previously Treated ALK-Positive Non-Small-Cell Lung Cancer
2020 · Todd M. Bauer, Alice T. Shaw, et al. · Targeted Oncology · 118
PDF
Intracranial and extracranial efficacy of lorlatinib in patients with ALK-positive non-small-cell lung cancer previously treated with second-generation ALK TKIs
2021 · E. Felip, A.T. Shaw, et al. · Annals of Oncology · 108
PDF
Nutrition support in cancer patients: a brief review and suggestion for standard indications criteria
2002 · Gerson Peltz · Nutrition Journal · 87
PDF
A Multilevel Analysis of Socioeconomic Status and Prostate Cancer Risk
2006 · Maureen Sanderson, Ann L. Coker, et al. · Annals of Epidemiology · 60
Lorlatinib for Previously Treated ALK-Positive Advanced NSCLC: Primary Efficacy and Safety From a Phase 2 Study in People’s Republic of China
2022 · Shun Lu, Qing Zhou, et al. · Journal of Thoracic Oncology · 36
OA 05.06 Phase 2 Study of Lorlatinib in Patients with Advanced ALK+/ROS1+ Non-Small-Cell Lung Cancer
2017 · B. Solomon, A. Shaw, et al. · Journal of Thoracic Oncology · 34
PDF
The Effect of Rifampin on the Pharmacokinetics and Safety of Lorlatinib: Results of a Phase One, Open-Label, Crossover Study in Healthy Participants
2019 · Joseph Chen, Huiping Xu, et al. · Advances in Therapy · 33
Lorlatinib Exposure‐Response Analyses for Safety and Efficacy in a Phase I/II Trial to Support Benefit–Risk Assessment in Non‐Small Cell Lung Cancer
2021 · Joseph Chen, Ana Ruiz‐Garcia, et al. · Clinical Pharmacology & Therapeutics · 29
PDF
Phase I trial of lorlatinib in patients with ALK-driven refractory or relapsed neuroblastoma: A New Approaches to Neuroblastoma Consortium study.
2020 · Kelly C. Goldsmith, Kimberly Kayser, et al. · Journal of Clinical Oncology · 29
BMS-911543, A Selective JAK2 Inhibitor: A Multicenter Phase 1/2a Study In Myelofibrosis
2013 · Animesh Pardanani, Andrew W. Roberts, et al. · Blood · 25
Diabetes, physical activity and breast cancer among Hispanic women
2010 · Maureen Sanderson, Gerson Peltz, et al. · Cancer Epidemiology · 25
LBA2 Lorlatinib vs crizotinib in the first-line treatment of patients (pts) with advanced ALK-positive non-small cell lung cancer (NSCLC): Results of the phase III CROWN study
2020 · B. Solomon, T.M. Bauer, et al. · Annals of Oncology · 24
Impact of lorlatinib on patient-reported outcomes in patients with advanced ALK-positive or ROS1-positive non-small cell lung cancer
2020 · Solange Peters, Alice T. Shaw, et al. · Lung Cancer · 19
OA02.03 Clinical Activity of Lorlatinib in Patients with ROS1+ Advanced Non-Small Cell Lung Cancer: Phase 2 Study Cohort EXP-6
2018 · S. Ou, A. Shaw, et al. · Journal of Thoracic Oncology · 18
Lorlatinib in previously treated anaplastic lymphoma kinase‐rearranged non–small cell lung cancer: Japanese subgroup analysis of a global study
2020 · Takashi Seto, Hidetoshi Hayashi, et al. · Cancer Science · 17
PDF
Lorlatinib in patients (Pts) with previously treated ALK+ advanced non-small cell lung cancer (NSCLC): Updated efficacy and safety.
2018 · Benjamin Besse, Benjamin J. Solomon, et al. · Journal of Clinical Oncology · 17
A review and characterization of the various perceptions of quality cancer care
2010 · Ann D. Colosia, Gerson Peltz, et al. · Cancer · 17
PDF
Analysis of the psychological impact of cancer-related symptoms on patients with non-small cell lung cancer
2016 · Mark S. Walker, Gerhardt M. Pohl, et al. · Psycho-Oncology · 16
Works count: 62
Citation count: 3,666
H-index: 19
I10-index: 27
Year
Topic
Type